Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have, within the last 4 years, been diagnosed with T2D based on the World Health Organization classification or other locally applicable diagnostic standards.
Have HbA1c ≥7% to ≤9.5% as determined by the central laboratory.
Have been on a stable treatment of metformin only at least 90 days preceding baseline
* with the minimum effective dose of ≥1500 mg/day, but not higher than the maximum approved dose per country-specific label, or
* \<1500 mg/day in case of intolerance of full therapeutic dose.
You may not be if
Have type 1 diabetes mellitus
Have a history of chronic or acute pancreatitis any time prior to study entry
Have a history of
* proliferative diabetic retinopathy
* diabetic macular edema, or
* no proliferative diabetic retinopathy requiring immediate or urgent treatment
Are at high risk for cardiovascular disease (CVD) in the investigator's opinion or have a history of any of these CV conditions prior to study entry
* peripheral vascular procedure (e.g., stenting or surgical revascularization)
* cerebrovascular accident (stroke), or congestive heart failure
Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over the counter, or alternative remedies
Have an estimated glomerular filtration rate (eGFR) \<30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label), calculated by chronic kidney disease-epidemiology equation as determined by central laboratory at screening.
Have been treated with any injectable glucagon-like peptide-1 (GLP-1) receptor agonists and insulin prior to screening.
* Exception: use of insulin for gestational diabetes or short-term use (\<14 days) for acute conditions such as acute illness, hospitalization, or elective surgery.
Clareo Health | A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
